Pralidoxime safety and toxicity in children.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Quail MT;Quail MT; Shannon MW
  • Source:
    Prehospital emergency care [Prehosp Emerg Care] 2007 Jan-Mar; Vol. 11 (1), pp. 36-41.
  • Publication Type:
    Journal Article; Review
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: Informa Healthcare Country of Publication: England NLM ID: 9703530 Publication Model: Print Cited Medium: Print ISSN: 1090-3127 (Print) Linking ISSN: 10903127 NLM ISO Abbreviation: Prehosp Emerg Care Subsets: MEDLINE
    • Publication Information:
      Publication: London : Informa Healthcare
      Original Publication: Philadelphia, PA : Hanley & Belfus, c1997-
    • Subject Terms:
      Drug-Related Side Effects and Adverse Reactions*; Antidotes/*poisoning ; Pralidoxime Compounds/*poisoning; Adolescent ; Antidotes/administration & dosage ; Antidotes/therapeutic use ; Child ; Child, Preschool ; Female ; Humans ; Male ; Pralidoxime Compounds/administration & dosage ; Pralidoxime Compounds/therapeutic use
    • Abstract:
      Background: Currently, the safety of pralidoxime administration via adult autoinjectors for pediatric patients has not been established. Up until 2000, the published literature did not recommend its usage for children less than 12 kg or under the age of 10 years old. Since 2000, limited published articles have emerged validating adult autoinjector usage for the pediatric victim, in extreme circumstances.
      Objective: We sought to determine whether adverse drug reactions (ADR) from pralidoxime administration to children occur.
      Method: Recurrent PubMed Medline literature search of all years were performed from 2001 to 2004 inclusive. The main search criteria were articles pertaining to U.S. children 16 years or younger who received pralidoxime. In addition, a review of 3 years (1999-2001) of detailed retrospective TESS exposure annual poison center data was obtained from the AAPCC.
      Results: Eighty-one children met inclusion criteria and received pralidoxime for suspected organophosphate poisoning. Two children (2.5%) expired. Three children (3.7%) were identified as having a potential adverse drug reaction; all were mild.
      Conclusion: The author's recognize this study possesses limitations that require its findings be interpreted with caution. Our data suggest that adverse drug reactions to pralidoxime treatment in children are rare. However, further investigation is needed to more firmly establish the safety of this antidote in children and for its use in the prehospital environment.
    • Number of References:
      26
    • Accession Number:
      0 (Antidotes)
      0 (Pralidoxime Compounds)
      P7MU9UTP52 (pralidoxime)
    • Publication Date:
      Date Created: 20061216 Date Completed: 20070323 Latest Revision: 20131121
    • Publication Date:
      20240829
    • Accession Number:
      10.1080/10903120601023289
    • Accession Number:
      17169874